This profile is built from public research funding records (CIHR, NSERC and SSHRC) and PubMed. We have not imported them from a University of Calgary directory, so their courses and email address may be missing. Find their university profile.
Research
Latest papers
NCBP2 and TFRC are novel prognostic biomarkers in oral squamous cell carcinoma.
Cancer gene therapy · 2023 · first author
Occupation and SARS-CoV-2 seroprevalence studies: a systematic review.
BMJ open · 2023
Latest funding
- $100,000
Middle East Respiratory Syndrome (MERS) seroprevalence in zoonotic reservoirs and in humans: implications for spillover risk and population underlying infection
CIHR · 2023 · Nominated PI
2 publications.
NCBP2 and TFRC are novel prognostic biomarkers in oral squamous cell carcinoma.
Arora R, Haynes L, Kumar M, McNeil R, Ashkani J, Nakoneshny SC, Matthews TW, Chandarana S, Hart RD, Jones SJM, Dort JC, Itani D, Chanda A, Bose P
Occupation and SARS-CoV-2 seroprevalence studies: a systematic review.
Boucher E, Cao C, D'Mello S, Duarte N, Donnici C, Duarte N, Bennett G, SeroTracker Consortium, Adisesh A, Arora R, Kodama D, Bobrovitz N
Middle East Respiratory Syndrome (MERS) seroprevalence in zoonotic reservoirs and in humans: implications for spillover risk and population underlying infection
Principal investigators: Arora, Rahul K
Keywords: Data Platform; Living Systematic Review; Middle East Respiratory Syndrome; One Health; Pandemic Preparedness; Seroepidemiology; Seroprevalence; Statistical Modeling; User Interviews; Zoonosis
From CIHR, NSERC and SSHRC funding decisions: CIHR since 2008, NSERC since 1991 and SSHRC since 1998, including their latest published competition results.
A short, specific email works best. This draft uses one of their recent papers; replace the parts in brackets with your own details before sending.